Wells Fargo analyst Larry Biegelsen downgraded Pulmonx to Equal Weight from Overweight with a price target of $14, down from $16. The firm says its thesis has played out while the management changes create uncertainty.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LUNG:
- Pulmonx Announces Executive Leadership Transition and Board Changes
- Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
- Pulmonx sees FY24 revenue $81M-$84M, consensus $78.93M
- Pulmonx reports Q4 EPS (36c), consensus (41c)
- Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
